Publisher
Springer International Publishing
Reference44 articles.
1. Abbott A (2008) Neuroscience: the plaque plan. Nature 456:161–164. https://doi.org/10.1038/456161a
2. Allsop D (2000) Introduction to Alzheimer’s disease. Methods Mol Med 32:1–21. https://doi.org/10.1385/1-59259-195-7:1
3. Alzforum (2012) Therapeutics: bapineuzumab. 27 Oct 2012. https://www.alzforum.org/therapeutics/bapineuzumab. Accessed 21 Jan 2023
4. Athira Pharma, Inc. (2022) Athira pharma announces topline results from ACT-AD phase 2 proof of concept study of fosgonimeton in mild-to-moderate Alzheimer’s disease [Press Release]. 22 June 2022. https://investors.athira.com/news-releases/news-release-details/athira-pharma-announces-topline-results-act-ad-phase-2-proof/. Accessed 23 Jan 2023
5. Bamford G (1993) Popper’s explications of ad hoc ness: circularity, empirical content, and scientific practice. Br J Philos Sci 44:335–355. https://doi.org/10.1093/bjps/44.2.335